TSE:AUP - Aurinia Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started C$8.35 -0.04 (-0.48 %) (As of 03/18/2019 04:00 PM ET)Previous CloseC$8.39Today's RangeC$8.28 - C$8.4552-Week RangeC$6.44 - C$10.47Volume34,888 shsAverage Volume86,556 shsMarket CapitalizationC$751.09 millionP/E Ratio-13.34Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada. Receive AUP News and Ratings via Email Sign-up to receive the latest news and ratings for AUP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange TSE Industry Technical & System Software Sub-IndustryN/A SectorComputer and Technology Current SymbolTSE:AUP Previous SymbolTSE:ISA CUSIPN/A CIKN/A Webwww.auriniapharma.com Phone+1-250-7084272Debt Debt-to-Equity RatioN/A Current Ratio20.93 Quick Ratio20.29Price-To-Earnings Trailing P/E Ratio-13.34 Forward P/E Ratio-10.31 P/E GrowthN/A Sales & Book Value Annual SalesC$466,000.00 Price / Sales1,611.78 Cash FlowC$1.59 per share Price / Cash Flow5.25 Book ValueC$1.47 per share Price / Book5.68Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares89,951,000Market CapC$751.09 million Next Earnings Date3/19/2019 (Confirmed) OptionableNot Optionable Aurinia Pharmaceuticals (TSE:AUP) Frequently Asked Questions What is Aurinia Pharmaceuticals' stock symbol? Aurinia Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AUP." When is Aurinia Pharmaceuticals' next earnings date? Aurinia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 19th 2019. View Earnings Estimates for Aurinia Pharmaceuticals. Has Aurinia Pharmaceuticals been receiving favorable news coverage? Media stories about AUP stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a coverage optimism score of 1.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future. Who are some of Aurinia Pharmaceuticals' key competitors? Some companies that are related to Aurinia Pharmaceuticals include Iress (IRE), GB Group (GBG), Emis Group (EMIS), SDL (SDL), Computer Modelling Group (CMG), Absolute Software (ABT), Wandisco (WAND), Ideagen (IDEA), Dotdigital Group (DOTD), Microgen (MCGN), TECSYS (TCS), IDOX (IDOX), Sopheon (SPE), Seeing Machines (SEE) and Oxford Metrics (OMG). What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Aurinia Pharmaceuticals (AUPH), Allena Pharmaceuticals (ALNA), TOP SHIPS (TOPS), Neovasc (NVCN), Biopharmx (BPMX), Aurora Cannabis (ACB), Advanced Micro Devices (AMD), NVIDIA (NVDA), Coherus Biosciences (CHRS) and Bio-Path (BPTH). Who are Aurinia Pharmaceuticals' key executives? Aurinia Pharmaceuticals' management team includes the folowing people: Dr. Richard M. Glickman, Founder, Chairman, Pres & CEO (Age 61)Mr. Michael R. Martin, Co-Founder & COOMr. Dennis Bourgeault CPA, C.A., CFO & Sec.Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.Dr. Neil Solomons M.D., Chief Medical Officer How do I buy shares of Aurinia Pharmaceuticals? Shares of AUP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is Aurinia Pharmaceuticals' stock price today? One share of AUP stock can currently be purchased for approximately C$8.35. How big of a company is Aurinia Pharmaceuticals? Aurinia Pharmaceuticals has a market capitalization of C$751.09 million and generates C$466,000.00 in revenue each year. What is Aurinia Pharmaceuticals' official website? The official website for Aurinia Pharmaceuticals is http://www.auriniapharma.com/. How can I contact Aurinia Pharmaceuticals? Aurinia Pharmaceuticals' mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company can be reached via phone at +1-250-7084272. MarketBeat Community Rating for Aurinia Pharmaceuticals (TSE AUP)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 189 (Vote Outperform)Underperform Votes: 127 (Vote Underperform)Total Votes: 316MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/18/2019 by MarketBeat.com StaffFeatured Article: How is the LIBOR rate calculated?